U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. CDER Offices and Divisions
  6. Office of Immunology and Inflammation (OII)
  1. CDER Offices and Divisions

Office of Immunology and Inflammation (OII)

The Office of Immunology and Inflammation (OII) consists of six review divisions:

The Immediate office oversees the development, review, and regulation of applications for drug and biologic products reviewed in these divisions.

The staff of OII consists of highly trained physicians, scientists and regulatory project managers with expertise in gastroenterology, dermatology, dental,  hepatology and nutrition, metabolism, pulmonology, allergy and critical care, and rheumatology and transplant medicine, pharmacology/toxicology, and regulatory affairs. These professionals work with specialists in other CDER scientific disciplines such as statistics, clinical pharmacology, epidemiology, chemistry, and drug safety to collaboratively review data on new treatments. 

OII is committed to facilitating rapid development, review, and action on promising new therapies. Scientists within the office are working intensively on incorporating innovations in pharmacogenomics, bioinformatics, and clinical trial design into the drug development process.

Contact Us

Mailing Address: 

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Immunology and Inflammation
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4177
Phone: (301) 796-2240
Fax: (301) 796-9838

Resources 



Back to Top